Sure is, and censorship of the most Orwellian sort.
Worse, it's run by mindless algorithms and happens seemingly at random often.
RE the market maker conspiracy theory....Nah. Look at the bigger market picture.
Chinese stocks have been in free fall , and they are the world's second largest economy.
All major markets are interlinked and what happens there affects us here.
Hoo boy! Way too much enthusiasm!
I'm a committed long, but keep it real please STV.
This is just another niche bio-tech company.
New technology/methodology could be invented tomorrow
and kick us to the sidelines surprisingly quickly.
This field is changing fast and lots of brilliant minds are working in it.
This is no solid old blue chip outfit.
Well, It's been an exciting run but the bus has left the station. Sold my position this morning, not because I wanted to......but had to. Bought at $3 ten years ago or so and enjoyed the fun. Thank you ILMN for my new home and I'll be back soon!!
$150B? That's a lot.
Are you talking about market capitalization? Because MC is $27B now, and a 7X increase in share price seems a little steep to me......You know, $1400 a share and all.
Or are you talking about sales? Because sales are about $2B right now, and increasing sales 75X would be pretty impressive!
Or are you talking about Enterprise Value? Because EV right now is also in the $27B range, since Cash is roughly equal to debt.
Just wondering, here...........
I am hoping ilmn goes down in the upcoming sell-off so I can buy more stock at a cheaper price. illumina is going to be one of the winners in the next 3 years no matter if the stock market in general, corrects or advances. Don't lose sight of the long term. Buy in times of weakness.
I am predicting that ilmn will be up over 100% within the next 2 to 3 years. imln is changing medicine as we know it. It would not surprise me to see it triple, but I will stick to my "conservative" prediction. Time will tell. I am going load up another 400 to 500 shares if it dips below $200 in the coming months.
You may want to stay on your LMNX board where clearly you are the man poster..just leave .
I think the price that Roche offered was only $45 per share. The Roche CE, Severin Schwann, is a notorious cheapskate. He made a massive blunder in failing to secure the purchase of illumina. ilmn will erode into Roche's market share as, ilmn CEO, Jay Flatley gears the company up to aggressively enter the diagnostic test market. Schwann should be fired for his miss-step.
Today ilmn just graduated its first 3 companies from its genomics incubator. This incubator will allow ilmn to keep and maintain its advantage in the current genomics revolution that is taking place in medicine. There is no doubt in my mind that illumina, in the near future, will be a $100 million company. Tigress Fnacial's price target of $539 per share will become a reality.
May want to peak at lmnx when you have a minute or two ... Look closely at their 77% gr.mgn. And 105% earnings growth, ex-1 time item. this is just gathering momentum. Price target on 80+ cents as forward guidance: $41+ . If using 100 p/e on 80 cents: $80/sh.; if using 50 p/e: $40/sh. the one-time item of settled litigation item on report was missed by alot of analysts that go off headline data and don't look deeper. they will react once price holds and moves higher. may be gapping again in next few days.
Norris, is there room for both Trovagene and Illumina's new interest, (mentioned in today's
press release) Urology Diagnostics Inc?
"Urology Diagnostics Incorporated is a genomics company from Oregon developing noninvasive urine sequencing diagnostics for screening and monitoring cancer."
I like it. They are expanding into diagnostics and soon into therapeutics. Market leader. All this bull about being expensive is non-sense. Eventually genetics and immunotherapy ( biotherapy ) will solve cancer....
I believe you are right in that it IS going to grow bigger. Some day it will be worth the market cap of $31B. But it's not worth that today.
Sales are $2B with a growth of about 25%.
$31B? No. Perhaps $20B. Today.